BCRX
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
BioCryst Pharmaceuticals, Inc.
- Nom
- BioCryst Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.0B
- Employés
- 435
- PDG
- Charles K. Gayer
- Site web
- https://www.biocryst.com
- Marché
- AVIRPHVSVIR
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-07-10 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-09 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-10 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2023-10-16 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
BCRX presents a compelling event-driven setup combining a meaningful M&A rumor catalyst (score 70, confidence 0.65) with a genuine financial turnaround story — the shift to 30%+ net profit margins in 2025 provides rare…
The first sentence of the analysis written for BCRX on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.06 · operating margin 39%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.8% | 97.2% | 98.6% | 97.6% | 95.4% | |
| Ebit Margin | 39.6% | 2.6% | -35.6% | -53.6% | -78.0% | |
| Ebitda Margin | 39.7% | 2.8% | -35.1% | -53.1% | -77.5% | |
| Operating Profit Margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | |
| Pretax Profit Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | |
| Continuous Operations Profit Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | |
| Net Profit Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | |
| Bottom Line Profit Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | |
| Current Ratio | 2.062 | 2.631 | 3.307 | 4.895 | 5.458 | |
| Quick Ratio | 2.035 | 2.581 | 3.115 | 4.634 | 5.306 | |
| Solvency Ratio | 0.419 | -0.091 | -0.231 | -0.291 | -0.264 | |
| Cash Ratio | 0.458 | 0.654 | 0.738 | 2.888 | 4.863 | |
| Price To Earnings Ratio | 6.190 | -17.488 | -5.076 | -8.632 | -13.447 | |
| Price To Earnings Growth Ratio | -0.016 | 0.275 | 0.450 | -0.296 | 2.443 | |
| Forward Price To Earnings Growth Ratio | -0.016 | 0.275 | 0.450 | -0.296 | 2.443 | |
| Price To Earnings Diluted Ratio | 6.446 | -17.488 | -5.076 | -8.632 | -13.447 | |
| Price To Earnings Diluted Growth Ratio | -0.017 | 0.275 | 0.450 | -0.296 | 2.443 | |
| Price To Book Ratio | -13.740 | -3.266 | -2.527 | -7.245 | -23.188 | |
| Price To Sales Ratio | 1.871 | 3.449 | 3.474 | 7.880 | 15.784 | |
| Price To Free Cash Flow Ratio | 5.000 | -29.248 | -11.831 | -13.077 | -17.163 | |
| Price To Operating Cash Flow Ratio | 4.963 | -29.880 | -12.101 | -13.186 | -17.451 | |
| Debt To Assets Ratio | 0.854 | 1.716 | 1.596 | 1.348 | 1.009 | |
| Debt To Equity Ratio | -3.683 | -1.768 | -1.811 | -2.517 | -5.545 | |
| Debt To Capital Ratio | 1.373 | 2.302 | 2.232 | 1.659 | 1.220 | |
| Long Term Debt To Capital Ratio | 1.387 | 2.487 | 2.281 | 1.672 | 1.224 | |
| Financial Leverage Ratio | -4.315 | -1.030 | -1.135 | -1.867 | -5.497 | |
| Working Capital Turnover Ratio | 3.724 | 1.484 | 0.876 | 0.620 | 0.462 | |
| Operating Cash Flow Ratio | 1.682 | -0.324 | -0.634 | -1.534 | -1.371 | |
| Operating Cash Flow Sales Ratio | 0.377 | -0.115 | -0.287 | -0.598 | -0.904 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.993 | 1.022 | 1.023 | 1.008 | 1.017 | |
| Debt Service Coverage Ratio | 4.363 | 0.081 | -1.078 | -1.479 | -2.091 | |
| Interest Coverage Ratio | 4.323 | -0.026 | -0.958 | -1.498 | -2.997 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -1.468 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.752 | -0.062 | -0.115 | -0.218 | -0.240 | |
| Capital Expenditure Coverage Ratio | 133.663 | -46.281 | -43.884 | -119.800 | -59.605 | |
| Dividend Paid And Capex Coverage Ratio | 133.663 | -46.281 | -43.884 | -119.800 | -59.605 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 5.713 | 178.861 | -16.038 | -17.872 | -21.108 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.8% | ▲0.6% | ▲0.5% |
| Ebit Margin | 39.6% | ▲37.0% | ▲64.6% |
| Ebitda Margin | 39.7% | ▲36.9% | ▲64.4% |
| Operating Profit Margin | 39.0% | ▲39.5% | ▲71.1% |
| Pretax Profit Margin | 30.6% | ▲49.9% | ▲83.2% |
| Continuous Operations Profit Margin | 30.2% | ▲49.9% | ▲83.4% |
| Net Profit Margin | 30.2% | ▲49.9% | ▲83.4% |
| Bottom Line Profit Margin | 30.2% | ▲49.9% | ▲83.4% |
| Current Ratio | 2.062 | ▼-0.569 | ▼-1.608 |
| Quick Ratio | 2.035 | ▼-0.546 | ▼-1.500 |
| Solvency Ratio | 0.419 | ▲0.509 | ▲0.510 |
| Cash Ratio | 0.458 | ▼-0.197 | ▼-1.462 |
| Price To Earnings Ratio | 6.191 | ▲23.679 | ▲13.881 |
| Price To Earnings Growth Ratio | -0.016 | ▼-0.291 | ▼-0.587 |
| Forward Price To Earnings Growth Ratio | -0.016 | ▼-0.291 | ▼-0.587 |
| Price To Earnings Diluted Ratio | 6.446 | ▲23.935 | ▲14.086 |
| Price To Earnings Diluted Growth Ratio | -0.017 | ▼-0.292 | ▼-0.588 |
| Price To Book Ratio | -13.740 | ▼-10.474 | ▼-3.747 |
| Price To Sales Ratio | 1.871 | ▼-1.577 | ▼-4.620 |
| Price To Free Cash Flow Ratio | 5.000 | ▲34.248 | ▲18.264 |
| Price To Operating Cash Flow Ratio | 4.963 | ▲34.843 | ▲18.494 |
| Debt To Assets Ratio | 0.854 | ▼-0.862 | ▼-0.451 |
| Debt To Equity Ratio | -3.683 | ▼-1.915 | ▼-0.618 |
| Debt To Capital Ratio | 1.373 | ▼-0.929 | ▼-0.385 |
| Long Term Debt To Capital Ratio | 1.387 | ▼-1.101 | ▼-0.423 |
| Financial Leverage Ratio | -4.315 | ▼-3.285 | ▼-1.546 |
| Working Capital Turnover Ratio | 3.724 | ▲2.240 | ▲2.291 |
| Operating Cash Flow Ratio | 1.683 | ▲2.007 | ▲2.119 |
| Operating Cash Flow Sales Ratio | 0.377 | ▲0.492 | ▲0.683 |
| Free Cash Flow Operating Cash Flow Ratio | 0.993 | ▼-0.029 | ▼-0.020 |
| Debt Service Coverage Ratio | 4.363 | ▲4.282 | ▲4.404 |
| Interest Coverage Ratio | 4.323 | ▲4.349 | ▲4.554 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲1.468 | ▲0.293 |
| Operating Cash Flow Coverage Ratio | 0.752 | ▲0.814 | ▲0.728 |
| Capital Expenditure Coverage Ratio | 133.663 | ▲179.944 | ▲160.844 |
| Dividend Paid And Capex Coverage Ratio | 133.663 | ▲179.944 | ▲160.844 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 5.713 | ▼-173.147 | ▼-20.198 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.64B | $1.55B | $1.15B | $2.13B | $2.48B | |
| Enterprise value | $1.99B | $2.29B | $1.87B | $2.57B | $2.57B | |
| EV / Sales | 2.27x | 5.08x | 5.63x | 9.49x | 16.35x | |
| EV / Op. cash flow | 6.02x | -44.04x | -19.61x | -15.88x | -18.08x | |
| EV / Free cash flow | 6.07x | -43.11x | -19.17x | -15.75x | -17.78x | |
| EV / EBITDA | 5.71x | 178.86x | -16.04x | -17.87x | -21.11x | |
| Net debt / EBITDA | 1.00x | 57.50x | -6.14x | -3.04x | -0.73x | |
| Current ratio | 2.06x | 2.63x | 3.31x | 4.89x | 5.46x | |
| Income quality | 1.25x | 0.58x | 0.42x | 0.66x | 0.77x | |
| Graham net-net | -$1 | -$3 | -$3 | -$2 | -$1 | |
| Tax burden | 98.7% | 102.2% | 100.1% | 101.1% | 101.2% | |
| Interest burden | 77.2% | -752.1% | 191.7% | 168.2% | 148.4% | |
| Working capital | $208.3M | $261.6M | $346.0M | $411.0M | $462.4M | |
| Invested capital | $227.3M | $281.4M | $366.9M | $419.6M | $477.6M | |
| Return on assets | 51.3% | -18.1% | -43.8% | -44.9% | -31.3% | |
| Operating ROA | 67.9% | -0.5% | -19.4% | -26.1% | -38.5% | |
| Return on tangible assets | 51.3% | -18.1% | -43.8% | -44.9% | -31.3% | |
| Return on equity | -221.4% | 18.7% | 49.7% | 83.9% | 172.0% | |
| Return on invested capital | 105.2% | -0.7% | -28.1% | -33.2% | -36.5% | |
| Return on capital employed | 107.2% | -0.8% | -28.3% | -33.4% | -36.7% | |
| Earnings yield | 16.1% | -5.7% | -19.7% | -11.6% | -7.4% | |
| Free cash flow yield | 20.0% | -3.4% | -8.5% | -7.6% | -5.8% | |
| Capex / Op. cash flow | 0.7% | -2.2% | -2.3% | -0.8% | -1.7% | |
| Capex / Depreciation | 177.7% | 90.2% | 131.0% | 94.0% | 306.9% | |
| Capex / Sales | 0.3% | 0.2% | 0.7% | 0.5% | 1.5% | |
| SG&A / Sales | 39.9% | 59.0% | 64.5% | 58.8% | 75.6% | |
| R&D / Sales | 19.0% | 38.7% | 65.3% | 93.5% | 132.9% | |
| Stock comp / Sales | 9.7% | 14.5% | 16.8% | 16.5% | 22.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 45d | 64d | 63d | 68d | 68d | |
| Days payables outstanding | 303d | 340d | 1636d | 795d | 1397d | |
| Operating cycle | 148d | 300d | 2309d | 1592d | 862d | |
| Cash conversion cycle | -155d | -40d | 673d | 798d | -536d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth —Supports BioCryst''s evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.
- 2026-10-02 BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast BioXcel Therapeutics (NASDAQ: BTAI - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of current
- 2026-09-21 Biopharma Stock With Layers of Technical Support in Place After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressure and support.
- 2026-09-18 BioCryst Eyes $1B Rare-Disease Future Through External Innovation BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event.
- 2026-09-18 4 Biotech Stocks to Watch as Potential Takeover Targets Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
- 2026-09-15 BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-11 BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity BioCryst Pharmaceuticals, Inc.''s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst''s royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.
- 2026-09-06 Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House''s latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
- 2026-09-01 BioCryst to Present at Upcoming Investor Conference RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
- 2026-09-01 Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 115,805 shares of the biotechnology company''s stock, valued at approximately $1,158,000. A